Antisense therapy for restenosis following percutaneous coronary intervention

Expert Opinion on Biological Therapy

Volumn 5, Issue 1, 2005, Pages 79-89

  Kipshidze, Nicholas ^a   Tsapenko, Mykola ^b   Iversen, Patrick ^c   Burger, Denis ^d  

^a LENOX HILL HOSPITAL   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^c AVI BIOPHARMA INC   (United States)

^d CEO   (United States)

Author keywords

Angioplasty; Antisense oligonucleotides; Gene therapy; Restenosis; Stem

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; AVI 4126; BASIC FIBROBLAST GROWTH FACTOR; CELL CYCLE PROTEIN; CELL CYCLE PROTEIN 2; COMPLEMENTARY RNA; CYCLIN DEPENDENT KINASE 2; CYCLINE; DACTINOMYCIN; DNA; DNA BINDING PROTEIN; MESSENGER RNA; MORPHOLINE DERIVATIVE; MYC PROTEIN; MYOSIN HEAVY CHAIN; OLIGOMER; PACLITAXEL; PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; POLOXAMER; PROTEIN C MYB; RIBOZYME; UNCLASSIFIED DRUG;

ARTERY INTIMA PROLIFERATION; CELL PROLIFERATION; CLINICAL TRIAL; DNA DENATURATION; DNA SPLICING; DNA TRANSCRIPTION; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG SAFETY; FEASIBILITY STUDY; GENE EXPRESSION REGULATION; GENE TRANSFER; HUMAN; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN SYNTHESIS; PROTO ONCOGENE; RESTENOSIS; REVIEW; RNA STABILITY; RNA TRANSLATION; SMOOTH MUSCLE FIBER; TRIPLE HELIX;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; CORONARY RESTENOSIS; GENE THERAPY; HUMANS; OLIGONUCLEOTIDES, ANTISENSE;

ANIMALIA; INSERTION SEQUENCES;

EID: 12244259715     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.5.1.79     Document Type: Review

References (87)

1. SIMONSEN M: Changing role for cardiac surgery as use of stems continues growth. Cardiovasc. Device Update (2003) 9:1-7.
2. TOPOL EJ, SERRUYS PW: Frontiets in interventional cardiology. Circulation (1998) 98:1802-1820.
3. SERRUYS PW, FOLEY DP, SUTTORP MJ et al.: A randomized comparison of the value of additional stenting after optimal balloon angioplasty for long coronary lesions. J. Am. Coll. Cardiol. (2002) 39:393-399.
4. VAN DEN BRAND MJ, RENSING BJ, MOREL MA et al.: The effect of completeness of revascularization on event-free survival at one-year in the ARTS trial. J. Am. Coll. Cardiol. (2002) 39:559-564.
5. NAKATANI M, TAKEYAMA Y, SHIBATA M et al.: Mechanisms of restenosis after coronary intervention. Difference between plain old balloon angioplasty and stenting. Cardiovasc. Pathol. (2003) 12:40-48.
6. GOLDBERG SL, LOUSSARARIAN A, DE GREGORIO J, DI MARIO C, ALBIERRO R, COLOMBO A: Predictors of diffuse and aggressive intrastent restenosis. J. Am. Coll. Cardiol. (2001) 37:1019-1025.
7. YLA-HERTTUALA S, MARTIN JF: Cardiovascular gene therapy. Lancet (2000) 355:213-222.
8. LIBBY P, SCHWARTZ D, BOGI E, TANAKA H, CLINTON SK: A cascade model for restenosis: special case of atherosclerosis progression. Circulation (1992) 86:47-52.
9. CLOWES AW, CLOWES MM, FINGERLE J, REIDLY MA: Regulation of smooth muscle cell growth in injured artery. J. Cardiovasc. Pharmacol. (1989) 14(Suppl. 6):S12-S15.
10. FINGERLE J, JOHNSON R, CLOWES AW, MAJESKY MW, REIDY MA: Roles of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery. Proc. Natl. Acad. Sci. USA (1989) 86:8412-8416.
11. NIKKARI ST, CLOWES AW: Restenosis after vascular reconstruction. Ann. Med. (1994) 26:95-100.
12. SCHWARTZ SM, DE BLOIS D, O'BRIEN RM: The intima - soil for restenosis and atherosclerosis. Circ. Res. (1997) 77:445-465.
13. AGATA J, ZHANG JJ, CHAO L: Adrenomedullin gene delivery inhibits neointima formation in rat artery after ballon angioplasty. Regul. Rep. (2003) 112:115-120.
14. KIPSHIDZE N, MOSES J, SHANKAR LR et al.: Perspectives on antisense therapy for the prevention of restenosis. Curr. Opin. Mol. Ther. (2001) 3:265-277.
15. KIPSHIDZE N, IVERSEN P, KEANE E et al.: Complete vascular healing and sustained suppression of neointimal thickening after local delivery of advanced c-myc antisense at six months follow-up in a rabbit balloon injury model. Cardiovasc. Radiat. Med. (2002) 3:26-30.
16. GEORGE SJ, ANDELINI GD, CAPOGROSSI MC et al.: Wild-type p53 gene transfer inhibits neointima formation in human saphenous vein by modulation of smooth muscle cell migration and induction of apoptosis. Gene Ther. (2001) 8:668-676.
17. MURAKAMI H, YAYAMA K, MIAO RQ et al.: Kallikrein gene delivery inhibits vascular smooth muscle cell growth and neointima formation in the rat artery after balloon angioplasty. Hypertension (1999) 34:164-170.
18. STEG GP, TAHLIL O, AUBAILLY N et al.: Reduction of restenosis after angioplasty in an atheromatous rabbit model by suicide gene therapy. Circulation (1997) 96:408-411.
19. HARELL RL, RAJANAYAGAM S, DOANES AM et al.: Inhibition of vascular smooth muscle cell proliferation and neointimal accumulation by adenovirus-mediated gene transfer of cytosine deaminase. Circulation (1997) 96:621-627.
20. ZOLDHELIY P, MCNATT J, SHELAT H et al.: Thromboresistence of balloon-injured porcine carotid arteries after local gene transfer of human tissue factor pathway inhibitor. Circulation (2000) 101:289-295.
21. VAN BELLE E, TIO FO, CHEN D et al.: Passivation of metallic stents after arterial gene transfer of phVEGF 165 inhibits thrombus formation and intimal thickening. J. Am. Coll. Cardiol. (1997) 29:1371-1379.
22. YOON J, WU CJ, HOMME J et al.: Local delivery of nitric oxide from an during stent to inhibit neointimal thickening in a porcine coronary injury model. Yonsei Med. J. (2002) 43:242-251.
23. FELDMAN MD, BO SUN, KOCI B et al.: Stent-based gene therapy. J. Long Term Eff. Med. Implants (2000) 10:47-68.
24. ZAMECNIK P, STEPHENSON M: Inhibition of Rous sarcoma virus replication and cell transformation by a specific deoxyoligonucleotide. Proc. Natl. Acad. Sci. USA (1978) 75:280-284. Describes the first attempt to inhibit gene expression using antisense ODNs.
25. WANG A, CREASY A, LARDNER M et al.: Molecular cloning of the complementary DNA for human tumor necrosis factor. Science (1985) 228:149-154.
26. MORISHITA R, KANEDA Y, OGIHARA T: Therapeutic potential of oligonucleotide-based therapy in cardiovascular disease. BioDrug (2003) 17(6):383-389.
27. HELENE C, TOULME JJ: Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochem. Biophys. Acta (1990) 1049:99-125.
28. STEIN CA, CHENG YC: Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science (1993) 261:1004-1012.
29. SHI Y, FAD A, GALLEON A et al.: Transcatheter delivery of c-myc antisense oligomers reduced neointimal formation in a porcine model of coronary artery balloon injury. Circulation (1994) 90:944-951. One of the first papers to discuss the efficacy of local c-myc antisense delivery to prevent intimal hyperplasia in vivo.
30. BENNETT MR, SCHWARTZ SM: Antisense therapy for angioplasty restenosis: some critical considerations. Circulation (1995) 92:1981-1993.
31. STEIN CA, TOKINSON JL, YAKUBOV L: Phosphorothioate oligodeoxynucleotides antisense inhibitors of gene expression? Pharmacol. Ther. (1991) 52:365-384.
32. BOLZIAU C, KURFIST R, CAZENAVE C, ROIG V, THOUNG NT, TOULME JJ: Inhibition of translation initiation by antisense oligonucleotides via an RNAase independent mechanism. Nucleic Acid Res. (1991) 19:1113-1119. Describes possible mechanism of the antisense inhibition through steric interference.
33. GOODCHILD J: Inhibition of gene expression by oligonucleotides. In: Oligonucleotides: Antisense Inhibitors of Gene Expression. Cohen J (Ed.), Macmillan Press, London, UK (1989):53-77.
34. KOZAK M: Influences of mRNA secondary structure on inhibition by eucaryotic ribosome. Proc. Natl. Acad. Sci. USA (1996) 83:2850-2854.
35. WAGNER R, NISHIKURA K: Cell cycle expression of RNA duplex unwinding activity in cells. Mol. Cell. Biol. (1988) 8:770-777.
36. DASH P, LOTAN L, KNAPP M, KANDEL ER, GOELET P: Selective elimination of mRNA in vivo: complementary oligodeoxynucleotides promote RNA degradation by RNAse-H like activity. Proc. Natl. Acad. Sci. USA (1987) 84:7896-7900.
37. DAGLE JM, WALDER JA, WEEKS DL: Target degradation of mRNA in Xenopus oocytes and embryos directed by modified oligonucleotides: studies of An2 and cyclin in embryogenesis. Nucleic Acid Res. (1990) 18:4751-4757.
38. MCMANNAWAY ME, NECKERS LM, LOKE SL et al.: Tumor-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide. Lancet (1990) 335:808-811.
39. BURGESS TL, FISHER EF, ROSS SL et al.: The antiproliferative effect of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a non antisense mechanism. Proc. Natl. Acad. Sci. USA (1995) 92(9):4051-4055.
40. SIMONS M, ROSENBURG RD: Antisense non-muscle, myosin, heavy chain and c-myb oligonucleotides suppress smooth muscle cell proliferation in vitro. Circ. Res. (1992) 70:835-843.
41. GUNN J, HOLT CM, FRANCIS SE et al.: The effect of oligonucleotides to c-myb on vascular smooth muscle cell proliferation and neointima formation after porcine coronary angioplasty. Circ. Res. (1997) 80:520-531.
42. SPEIR E, EPSTEIN SE: Inhibition of smooth muscle cell proliferation by an antisense deoxyougonucleotide targeting the mRNA coding proliferating cell nuclear antigen. Circulation (1992) 86:538-547.
43. SIMONS M, EDELMAN ER, ROSENBERG RD: Antisense PCNA oligonucleotides inhibit neointimal hyperplasia in a rat carotid artery injury model. J. Clin. Invest. (1994) 93:2351-2356.
44. SUGIKI H: Suppression of vascular smooth muscle cell proliferation by an antisense oligonucleotide against PDGF receptor. Hokkaido Igaku Zasshi (1995) 70(3):485-495.
45. HANNA AK, FOX JC, NECKLIS DG et al.: Antisense basic fibroblast growth factor gene transfer reduces neointimal thickening after arterial injury. J. Vasc. Surg. (1997) 25(2):320-325.
46. MANDIYAN S, SCHUMACHER C, CIOFFI C et al.: Molecular and cellular characterization of baboon C-Raf as target for antiproliferative effects of antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. (1997) 7(6):539-548.
47. BIRO S, FU YM, YU ZX, EPSTEIN SE: Inhibitory effects of oligodeoxynucleotides targeting c-myc RNA on smooth muscle cell proliferation and migration. Proc. Natl. Acad. Sci. USA (1993) 90:654-658.
48. DAUM T, ENGELS JW, MAG M et al.: Antisense deoxynucleotide: inhibitor of splicing of mRNA of human immunodeficiency virus. Int. Virology (1992) 89:7031-7035.
49. SIMONS M, EDELMAN ER, DEKEYSER J-L, LANGER R, ROSENBERG RD: Antisense c-myb oligonucleotides inhibits intimal arterial smooth muscle cell accumulation in vivo. Nature (1992) 359:67-70.
50. MORISHITA R, GIBBONS GH, ELLISON KE et al.: Single intraluminal delivery of antisense cdc kinase PCNA results in chronic inhibition of neointimal hyperplasia. Proc. Natl. Acad. Sci. USA (1993) 90:8474-8478.
51. BAYEVER E, IVERSEN PL, BISHOP MR et al.: Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a Phase I trial. Antisense Res. Dev. (1993) 4(4):383-390.
52. AGROTIS A, KANELLAKIS P, KOSTOLIAS G et al.: Proliferation of neointimal smooth muscle cells after artetial injury: dependency on interaction between fibroblast growth factor receptor-2 and fibroblast growth factor-9. J. Biol. Chem. (2004) 279(40):42221-42229.
53. BLINDT R, BOSSERHOFF AK, DAMMERS J et al.: Downregulation of N-cadherin in the neointima stimulates migration of smooth muscle cells by RhoA deactivarion. Cardiovasc. Res. (2004) 62(1):212-222.
54. SUMMERTON J, STEIN D, HUANG B, MATTHEWS P, WELLER D, PARTRIDGE M: Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems. Antisense Nucleic Add Drug Dev. (1997) 7:63-70.
55. ABE J, ZHOU W, TAGUCHI J: Suppression of neointimal smooth muscle cell accumulation in vivo by antisense cdc2 and cdk2 oligonucleotides in rat carotid artery. Biochem. Biophys. Commun. (1994) 198:16-24.
56. ROBINSON KA, CHRONOS NA, SCHIEFFER E et al.: Endoluminal local delivery of PCNA/cdc2 antisense oligonucleotides by porous balloon catheter does not affect neointima formation or vessel size in the pig coronary artery model of post angioplasty restenosis. Cathet. Cardiovasc. Diagn. (1997) 41:348-353.
57. SCHMIDT A, SINDERMANN J, PEYMAN A et al.: Sequence specific antiproliferative effects of antisense and end-capping modified antisense oligodeoxynucleotides targeted against the 5′-terminus of Basic-fibroblast growth factor mRNA in coronary smooth muscle cells. Eur. J. Biochem. (1997) 248(2):543-549.
58. TANAKA S, AMLING M, NEFF L et al.: c-cbl downstream of c-src in a signaling pathway necessary for bone resorption. Nature (1996) 383:528-531.
59. PEYMAN A, HELSBERG M, KRETZSCHMAR G, MAG M, RYTE A, UHLMANN E: Nuclease stability as dominant factor in the antiviral activity of oligonucleotides directed again HSV-1 IEI10. Antiviral Res. (1997) 33:135-139.
60. STEIN D, FOSTER E, HUANG SB, WELLER D, SUMMERTON J: A specificity comparison of four antisense types: morpholino, 2′-O methyl RNA, DNA and phosphorothioate DNA. Antisense Nucleic Acid Drug Dev. (1997) 7:151-157.
61. HOLT JT, RENDER RL, NELHUS AW: An oligomer complementary to c-myc RNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation. Mol. Cell. Biol. (1988) 8:963-973.
62. VILLA AE, GUZMAN LA, POPTIC EJ et al.: Effects of antisense c-myb oligonucleotides on vascular smooth muscle cell proliferation and response to vessel wall injury. Circ. Res. (1995) 76:505-513.
63. MULLER DW: The role of protooncogenes in coronary restenosis. Prog. Cardiovasc. Dis. (1997) 40(2):117-128.
64. WICKSTROM E: Antisense c-myc inhibition of lymphoma growth. Antisense Nucleic Acid Drug Dev. (1997) 7(3):225-228.
65. CAZENAVE C, LOREAU N, THUONG NT, TOULME JJ: Enzymatic amplification of translation inhibition of rabbit beta-globin mRNA mediated by anti-messenger oligodeoxynucleotides covalently linked to intercalating agents. Nucleic Acid Res. (1995) 15(12):4717-4736.
66. SHAW JP, KENT K, BIRD J, FISHBACK J, FROEHLER BF: Modified deoxyoligonucleotide stable to exonuclease degradation in serum. Nucleic Acids Res. (1991) 19:747-750.
67. OTT J, ECKSTEIN F: Protection of oligonucleotide primers against degradation by DNA polymerase I. Biochemistry (1987) 26(25):8237-8241.
68. HOKE GD, DRAPER K, FREIER SM et al.: Effect of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection. Nucleic Acid Res. (1991) 20:5743-5748.
69. CORNISH KG, IVERSEN PL, SMITH L, ARNESON M, BAYEVER E: Cardiovascular effects of a phosphorothioate oligonucleotide with sequence antisense to p53 in the conscious rhesus monkey. Pharmacol. Commun. (1993) 3:239-247.
70. GALBRAITH WM, HOBSON WC, GICLAS PC, SCHECHTER PJ, AGRAWAL S: Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res. Dev. (1994) 4:201-206.
71. HENRY SP, BOLTE H, AULETTA C, KORNBURST DJ: Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four week study in cynomolgus monkeys. Toxicology (1997) 120:145-155.
72. IVERSEN PL, CORNISH KG, IVERSEN LJ, MATA JE, BYLUND DB: Bolus intravenous injection of phosphorothioate oligonucleotides causes hypotension by acting as a1-adrenergic receptor antagonists. Toxicol. Appl. Pharmacol. (1999) 160:289-296.
73. HEDIN U, WAHLBERG E: Gene therapy and vascular disease: potential applications in vascular surgery. Eur. J. Vasc. Endovasc. Surg. (1997) 13:101-111.
74. KIPSHIDZE NN, IVERSEN P, KIM HS et al.: Advanced c-myc antisense (AVI-4126)-eluting phosphorylcholine-coated stent implantation is associated with complete vascular healing and reduced neointimal formation in the porcine coronary restenosis model. Catheter Cardiovasc. Interv. (2004) 61(4):518-527.
75. ZHANG XX, CUI CC, XU XG, HU XS, FANG WH, KUANG BJ: In vivo distribution of c-Myc antisense oligonucleotides local delivered by gelatin-coated platinum-indium stent in rabbits and its effect on apoptosis. Chin. Med. J. (Engl.) (2004) 117(2):258-263.
76. PORTER TR, IVERSEN PL, LI S, XIE F: Interaction of diagnostic ultrasound with synthetic oligonucleotide-labeled perfluorocarbon-exposed sonicated dextrose albumin microbubbles. J. Ultrasound Med. (1996) 15:577-584.
77. MANN MJ, WHITTEMORE AD, DONALDSON MC et al.: Ex vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet (1999) 354(9189):1493-1498.
78. KUTRYK MJ, FOLEY DP, VAN DEN BRAND M et al.: Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: results of the randomized investigation by the Thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) trial. J. Am. Coll. Cardiol. (2002) 39(2):281-287. ITALICS trial result. This was the first clinical experience with local delivery of an antisense compound in coronary arteries using a local delivery catheter.
79. HUDZIAK RM, BAROFSKY E, BAROFSKY DF et al.: Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev. (1996) 6:267-272.
80. HUDZIAK RM, SUMMERTON J, WELLER DD, IVERSEN PL: Antiproliferative effects of steric blocking phosphorodiamidate Morpholino antisense agents directed against c-myc. Antisense Nucleic Acid Drug Dev. (2000) 10:163-176.
81. DANI C, BLANCHARD JM, PIECHACZYK M, EL SABOUTY S, MARTY L, JEANTEUR P: Extreme instability of myc mRNA in normal and transformed human cells. Proc. Natl. Acad. Sci. USA (1984) 81:7046-7050.
82. KIPSHIDZE N, KEANE E, STEIN D et al.: Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury-model. Catheter. Cardiovasc. Interv. (2001) 54:247-256.
83. KIPSHIDZE NN, KIM H-S, IVERSEN P et al.: Intramural delivery of advanced antisense oligonucleotides with infiltrator catheter inhibits c-myc expression and intimal hyperplasia in the porcine stent restenosis model. J. Am. Coll. Cardiol. (2002) 39(10):1686-1691.
84. SHEPPARD R, EISENBERG MJ: Intracoronary radiotherapy for restenosis. N. Engl. J. Med. (2001) 344(4):295-297.
85. HERDEG C, OBERHOFF M, BAUMBACH A et al.: Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. J. Am. Coll. Cardiol. (2000) 35(7):1969-1976.
86. KIPSHIDZE NN, PORTER TR, DANGAS G et al.: Systemic targeted delivery of antisense with perflourobutane gas microbubble carrier reduced neointimal formation in the porcine coronary restenosis model. Cardiovasc. Radiat. Med. (2003) 4(3):152-159.
87. KIPSHIDZE NN, OVERLIE P, DUNLAP T et al.: First human experience with local delivery of novel antisense AVI-4126 with infiltrator catheter in de novo native and restenotic coronary arteries: six-month clinical and angiographic follow-up from AVAIL study. Circulation (2004) 110(17):III-757. Abstract. AVAIL trial result.